Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017.

CONCLUSIONS: Relative to the estimated costs of drug development, the costs of these oncology pivotal trials were modest, with trials that produced more valuable scientific information costing more than their counterparts.
PMID: 32114790 [PubMed - as supplied by publisher]

Source: Clinical Trials - February 28, 2020 Category: Research Authors: Hsiue EH, Moore TJ, Alexander GC Tags: Clin Trials Source Type: research